C - Chemistry – Metallurgy – 12 – P
Patent
C - Chemistry, Metallurgy
12
P
C12P 21/08 (2006.01) A61K 39/395 (2006.01) C07K 16/00 (2006.01)
Patent
CA 2597924
The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, using therapeutic antibodies that bind to the human CD 19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD 19 antibodies of the IgGl or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD 19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgGl, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD 19 antibodies.
L'invention porte sur des compositions immunothérapeutiques et des méthodes de traitement de maladies et troubles liées aux lymphocytes B chez l'homme, tels que non exclusivement les lymphomes B utilisant des anticorps thérapeutiques se fixant à l'antigène humain CD 19 et médiant l'ADCC humaine. L'invention porte également sur des préparations pharmaceutiques comprenant un anticorps anti CD-19 humain ou humanisé des isotypes humains IgGl ou IgG3. L'invention porte également sur des préparations pharmaceutiques comprenant un anticorps anti CD-19 humain ou humanisé des isotypes humains IgG2 ou IgG4, qui de préférence médie l'ADCC humaine. L'invention porte également sur des préparations pharmaceutiques comprenant un anticorps anti CD-19 chimérisé des isotypes humains IgGl, IgG2, IgG3, ou IgG4, qui médie l'ADCC humain. Dans ses variantes préférées, l'invention porte sur des préparations pharmaceutiques comprenant des anticorps monoclonaux humains, humanisés ou chimérisés.
Gron Hanne
Hamaguchi Yasuhito
Tedder Thomas F.
Yazawa Norihito
Borden Ladner Gervais Llp
Duke University
LandOfFree
Anti-cd19 antibodies and uses in oncology does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-cd19 antibodies and uses in oncology, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-cd19 antibodies and uses in oncology will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1349893